0.95
-6.47%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About HCW Biologics
From its filings with the US Securities and Exchange Commission
HCW Biologics is based in Miramar, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker HCWB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $54,232 and a net loss of $8.0m. At that date it held total assets of $24.5m and shareholders' equity of $2.8m.
HCW Biologics Inc. (“HCW Biologics” or the “Company”) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. We have created novel compounds that represent a new class of drugs that we believe have the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. Among other things, we have begun commercialization of certain commercial-ready proprietary compounds for use as reagents in the production of immunotherapeutics for the treatment of infectious diseases and cancer. We want our products to improve patients’ healthspan as well as their quality of life, and possibly extend longevity.
Chronic inflammation is believed to be a significant contributing factor to the cause for many diseases and conditions that diminish health span and quality of life. The induction and retention of low-grade inflammation in the human body is mainly the result of persistent activation of immune cells and the accumulation of non-proliferative but metabolically active senescent cells.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Jul 2021
- Employees
- 44
- Website
- hcwbiologics.com ↗
- Head office
- 2929 N COMMERCE PKWY, MIRAMAR, FL, 33025
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Scott GarrettIndependent Chairman of the Board$70,570
- Dr. Hing WongChief Executive Officer, Founder, Director, since 2018$368,188
- Ms. Rebecca ByamChief Financial Officer$154,236
- Mr. Lee FlowersSenior Vice President - Business Development
- Dr. Peter RhodeChief Scientific Officer, Vice President - Clinical Operations$261,667
- Ms. Lisa GilesIndependent Director$50,570
- Mr. Rick GreeneIndependent Director$60,570
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HCW9218 is in two clinical trials for treating senescent cells and SASP factors.
- HCW9302 activates regulatory T cells to suppress immune responses.
- The TOBI discovery platform generates novel multi-functional fusion molecules.
Weaknesses
- The company has only 44 employees, limiting operational capacity.
- The IPO listing date of 20 July 2021 indicates a relatively new market presence.
- Miramar, Florida, is a small city with limited biotech infrastructure.
Opportunities
- The Health Care sector offers growth in age-related disease treatments.
- The US market provides a large patient population for immunotherapies.
- Biotechnology industry trends support novel immunotherapy development.
Threats
- Chronic low-grade inflammation is linked to multiple age-related diseases.
- Competition in the Health Care sector could increase with new entrants.
- Regulatory hurdles may delay clinical trial approvals for HCW9218 and HCW9302.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.